Effects of acute treatments with the serotonin 2A antagonist M100907 alone or in combination with the serotonin 2C agonist WAY163909 on methamphetamine self-administration in rhesus monkeys.

MLA

Odabas-Geldiay, Melis, et al. “Effects of Acute Treatments with the Serotonin 2A Antagonist M100907 Alone or in Combination with the Serotonin 2C Agonist WAY163909 on Methamphetamine Self-Administration in Rhesus Monkeys.” Drug & Alcohol Dependence, vol. 194, Jan. 2019, pp. 252–56. EBSCOhost, https://doi.org/10.1016/j.drugalcdep.2018.10.018.

APA

Odabas-Geldiay, M., Shields, H., Berro, L. F., Rice, K. C., & Howell, L. L. (2019). Effects of acute treatments with the serotonin 2A antagonist M100907 alone or in combination with the serotonin 2C agonist WAY163909 on methamphetamine self-administration in rhesus monkeys. Drug & Alcohol Dependence, 194, 252–256. https://doi.org/10.1016/j.drugalcdep.2018.10.018

Chicago

Odabas-Geldiay, Melis, Hannah Shields, Lais F. Berro, Kenner C. Rice, and Leonard L. Howell. 2019. “Effects of Acute Treatments with the Serotonin 2A Antagonist M100907 Alone or in Combination with the Serotonin 2C Agonist WAY163909 on Methamphetamine Self-Administration in Rhesus Monkeys.” Drug & Alcohol Dependence 194 (January): 252–56. doi:10.1016/j.drugalcdep.2018.10.018.